Leech Extracts (Piyavit)

The salivary gland secretion (SGS) of Hirudo medicinalis is a multicomponent composite of natural hemostasis regulators. A natural question arose: could SGS be harvested, preserved, and administered as a stand-alone pharmaceutical? Early efforts to collect and store isolated SGS proved unsuccessful — lyophilization and cold storage reduced the activity of the secretion substantially (Baskova, 1992). This loss of activity during conventional preservation methods prompted a fundamentally different approach: rather than isolating SGS alone, the entire leech body would serve as the source material.

A fundamental distinction must be drawn between the mechanism of action of piyavit and the mechanism of action of SGS delivered during hirudotherapy. This distinction has important implications for clinical interpretation. Therapeutic effects observed during hirudotherapy cannot be assumed to predict the effects of oral piyavit, and vice versa. The two modalities should be evaluated independently on the basis of their respective preclinical and clinical evidence.

Piyavit is prepared from whole lyophilized Hirudo medicinalis. The dried leech powder retains the principal biologically active components of SGS — including hirudin, eglins, bdellins, destabilase, and prostanoids — as well as proteinase inhibitors from the intestinal canal and body tissues. The lyophilization process preserves protein structure and function while removing water, creating a stable solid matrix that resists degradation at refrigerator temperatures for multiple years.

The formulation also retains the antithrombin activity of hirudin. At a protein concentration of 0.8 mg/mL in physiological saline, piyavit doubles the fibrinogen clotting time by thrombin from 30 seconds (control) to 60-70 seconds (Baskova, 1986). The anti-inflammatory implications of elastase and cathepsin G inhibition are significant: neutrophil serine proteinases play a central role in tissue destruction during acute and chronic inflammatory processes, including arthritis, acute respiratory distress syndrome, and diabetic vascular complications.

The pharmacodynamic profile of piyavit encompasses multiple activities, reflecting the multicomponent nature of the preparation. These properties have been established through in vitro experimentation and animal studies conducted over approximately 15 years (1986-2001). The polyfunctionality of piyavit — attributable to its multicomponent composition — was considered its principal advantage. The original clinical investigators noted that hemostatic changes of similar magnitude typically require concurrent use of multiple conventional agents (anticoagulants, antiplatelet drugs, phlebotropic agents, anti-inflammatory agents), each carrying its own side effect profile and dosing complexity.

Kameneva et al. (1988, 1995) conducted comparative experiments evaluating piyavit extract versus unfractionated heparin as blood stabilizers. In these experiments, 1 mL of blood was stabilized with either 5 U of unfractionated heparin or 5-6 mg of protein from aqueous piyavit extract (ratio 1:9).

In a separate series, Baskova et al. (1995) demonstrated inhibition of platelet aggregation in platelet-rich rat plasma by piyavit extract. At a protein concentration of 0.01 mg/mL: maximum aggregation amplitude decreased nearly 6-fold (from 17.73 ± 12.31 Ohm to 3.43 ± 0.97 Ohm; n=6; p=0.002), aggregation rate decreased more than 3-fold (from 21.75 ± 19.6 Ohm/min to 6.22 ± 1.68 Ohm/min; p=0.038), while lag period duration did not differ from control.

The antithrombotic and thrombolytic properties of piyavit have been established through three complementary experimental models: a prethrombotic state model demonstrating state-dependent activity, the laser-induced arteriolar thrombosis model (performed at the University of Bordeaux, France) confirming protection with high statistical significance (p<0.0001), and the Wessler model of jugular vein thrombosis demonstrating dose-dependent thrombolysis without hemorrhage.

The presence of prostacyclin analogs (detectable as 6-keto-PgF1α by enzyme immunoassay) provides a mechanistic link: inhibition of arterial thrombus formation is mediated at least in part by prostacyclin-like substances that block platelet aggregation. Prostaglandins were previously demonstrated in both the SGS and the body of the leech (Baskova & Nikonov, 1987), reinforcing the rationale for whole-organism rather than head-only extraction.

The anti-atherosclerotic potential of piyavit was evaluated in a 5-month chronic dosing study in rats maintained on an atherogenic diet (Baskova et al., 1989; Bazazyan, 1982).

The immunologic effects of piyavit were characterized in three experimental systems: in vivo animal studies using standardized immunotoxicologic methods, blood cell culture experiments (MT4 lymphoblastoid cells and human PBMC), and neutrophil phagocytosis assays. The net immunologic profile — T-cell stimulation combined with B-cell suppression — qualifies as immunomodulatory rather than purely immunosuppressive or immunostimulatory.

SGS demonstrates substantial anticomplementary activity via the classical pathway of complement activation, both with and without prior incubation. Activity is less pronounced via the alternative pathway. Both activities are dose-dependent (Baskova et al., 1988). A 67-kDa protein subsequently isolated from whole leech extracts inhibits the activity of C1s, a subcomponent of complement component C1 (Tikhonenko, 2000). The proposed biological function is protection of the leech's symbiotic microflora (Aeromonas spp.) from the lytic action of the host's complement system.

Three distinct CNS-related properties have been documented for piyavit: stimulation of neurite outgrowth, analgesic activity via intranasal delivery, and enhancement of conditioned reflex memory. All three are supported by the confirmed ability of piyavit components to cross the blood-brain barrier, as demonstrated by tritium-labeling studies showing brain radioactivity exceeding blood radioactivity at 3 hours post-administration.

The rationale for investigating piyavit in diabetes rests on two converging lines of evidence: (1) immunomodulatory properties relevant to the autoimmune pathogenesis of type 1 diabetes (Green & Warzee, 2002; Rosmalen et al., 2002), and (2) broad-spectrum proteinase inhibition relevant to vascular complications of diabetes.

Because piyavit is a multicomponent formulation, classical single-analyte pharmacokinetics cannot be applied. Instead, Kotlova et al. (1999) used tritium (³H) labeling by the thermal activation method, distributing the radioactive label uniformly among the formulation's components.

The safety profile of piyavit has been characterized through acute toxicity studies, a 6-month chronic toxicity evaluation in two species, reproductive safety testing, and uterine contractility assessment. These studies were conducted primarily at the All-Union Scientific Center for Safety of Biologically Active Substances (Kupavna) under the direction of Berezovskaya.

The transition from animal pharmacology to human clinical investigation occurred in Russian clinical centers during the 1990s. The studies reviewed in this section were not designed to contemporary FDA standards: they lacked randomization, blinding, and placebo controls. They were conducted in single centers with modest sample sizes. Yet the clinical data they generated are consistent with the preclinical pharmacology and merit documentation as a research foundation.

A direct comparison of hemorheologic effects in patients with great saphenous vein thrombophlebitis demonstrated more pronounced improvements in blood viscosity and ESR in the piyavit group after 7 days compared with the phenindione group after 14 days (Kameneva et al., 1995).

In the controlled study of 42 patients undergoing prosthetic heart valve replacement (Baskova et al., 1997), the piyavit + phenindione group demonstrated a progressive hypocoagulable state while the control group (phenindione alone) exhibited hypercoagulation that gradually intensified through postoperative day 14. Specific hemostatic changes in the treatment group included decreased fibrinogen levels, prolonged thrombin time, prolonged aPTT on postoperative days 3-4, decreased prothrombin index, increased antithrombin III levels, and restored or increased fibrinolytic activity, with no decrease in platelet count from aggregation.

The clinical trial report, signed by Prof. Kaidash (Head, Cardiac Surgery Department, Vishnevsky Institute of Surgery), concluded that piyavit could potentially replace salicylates and other antiplatelet agents as combination therapy with indirect anticoagulants, and "given its pronounced effects on various components of the hemostatic system, the formulation could potentially be used as monotherapy in the postoperative period without other medications affecting blood coagulation. However, this question requires further study."

Magomedov and Magomedova (2001) reported 5 years of clinical experience with piyavit for prevention of DVT and pulmonary thromboembolism in more than 150 patients undergoing abdominal surgery, including emergency procedures and operations for bleeding gastric and duodenal ulcers. Over the entire observation period: zero deaths from postoperative DVT complications, zero deaths from postoperative pulmonary embolism, and zero fatalities from PE in pregnant women before or after cesarean section. While the absence of a formal control group limits interpretability, the zero-event rate across more than 150 patients over 5 years is noteworthy for a high-risk surgical population.

Tanashyan et al. (1997) administered piyavit to three groups of 20 patients each, classified by severity of cerebrovascular disease. Groups II (chronic cerebrovascular disease) and III (initial manifestations of cerebral blood supply insufficiency) received piyavit as monotherapy. Group I (acute cerebrovascular accident) received piyavit in addition to standard therapy. Treatment duration was 14 days.

The most significant changes were observed in the monotherapy groups (II and III): increased fibrinolytic activity of the euglobulin fraction, increased plasminogen activator content, and changes in soluble fibrin levels. Blood viscosity decreased in all three groups. Hemoglobin decreased in Groups II and III, a possible hemodilution effect. Group III showed a trend toward decreased ADP-induced platelet aggregation.

Two pilot investigations explored piyavit in conditions where its immunomodulatory and anti-inflammatory properties provide a specific rationale: renal allograft delayed recovery (where immunosuppression, antithrombotic action, and anti-inflammatory effects converge) and cystic fibrosis (where neutrophil elastase inhibition addresses the primary mechanism of pulmonary destruction).

The following table summarizes all published clinical studies conducted with oral piyavit capsules. Evidence levels are classified as: III = controlled, non-randomized; IV = prospective case series without controls; V = case reports/pilot data.

Piyavit is registered in Russia (Ministry of Health registration No. 94/302/6, re-registered 2001; No. 211-6940-6) for two indications: treatment and prevention of superficial vein thrombophlebitis, and diabetic micro- and macroangiopathies as part of comprehensive therapy. It is produced by LLC "GirudIN" in Balakovo, Saratov Oblast, Russia.

The regulatory precedent for animal-derived, multicomponent biological formulations exists. The challenge for a piyavit-type product would be analytical standardization — demonstrating batch-to-batch consistency of a complex biological matrix to FDA standards. Modern analytical technologies (high-resolution mass spectrometry, proteomic profiling, functional bioassay panels) provide tools not available when piyavit was originally developed.

At the time of original publication (2004), collaborative efforts with multiple Moscow medical institutions were underway to prepare documentation for additional piyavit dosage forms. The status of these development efforts beyond 2004 is not documented in available sources.

Additionally, piyavit substance was used by some clinicians for preparation of extracts for iontophoresis applications, and served as a component in various cosmetic products.